TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02770222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
Study: NCT03313193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure for Children in Treatment for a Childhood Cancer
Description: This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for \~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
Study: NCT02770222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
Study: NCT02343796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibreglass reinforced composite restoration-everStick
Description: For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everStick
Description: GC, Belgium
Study: NCT02286479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop drainage
Description: In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
Study: NCT04863807

Intervention type: PROCEDURE
Intervention: Regional Anaesthesia
Description: Thoracic epidural/Erector Spinae block/Serratus Anterior block

Intervention type: PROCEDURE
Intervention: Regional Anaesthesia
Description: Thoracic epidural/Erector Spinae block/Serratus Anterior block

Intervention type: PROCEDURE
Intervention: Regional Anaesthesia
Description: Thoracic epidural/Erector Spinae block/Serratus Anterior block
Study: NCT00696566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Rifampicin
Description: Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days
Study: NCT03166956

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glutamine and vitamin C enteral supplement
Description: Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine and vitamin C enteral supplement
Description: Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
Study: NCT02228122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquacel® Ag+ Extra
Description: Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
Study: NCT02029547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir (18F)
Description: No Florbetapir (18F) will be administered in this study.
Study: NCT01640561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISC
Description: The Mediational Interventions for Sensitizing Caregivers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UCOBAC
Description: This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
Study: NCT03983005

Intervention type: PROCEDURE
Intervention: EUS-B-FNA
Description: Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
Study: NCT02919605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of Pentamidine
Description: The patients will come to the hospital to take a single dose of the Pentamidine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two doses of Pentamidine
Description: The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Three doses of Pentamidine
Description: The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
Study: NCT02079870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Solution for subcutaneous (s.c. - under the skin) injection
Study: NCT03400553

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood analysis
Description: The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
Study: NCT01677065

Intervention type: DRUG
Intervention: Oxycodone controlled-release test formulation
Description: single dose administration of test formulation under fasted conditions

Intervention type: DRUG
Intervention: Immediate-release reference drug
Description: single dose administration of reference drug under fasted conditions
Study: NCT04807530

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TMS
Description: The investigators will use the NEXSTIM NAVIGATED BRAIN STIMULATION (NBS) SYSTEM to apply 10 Hz nrTMS to healthy controls (HC) and schizophrenia patients (SZ)
Study: NCT00231933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered planning (PCP)
Description: PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered planning (PCP)
Description: PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community integration (CI)
Description: CI includes recovery group sessions and community integration activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Illness management recovery (IMR)
Description: IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness management recovery (IMR)
Description: IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness management recovery (IMR)
Description: IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
Study: NCT02117817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT02350543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study: NCT01954290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan
Description: Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
Study: NCT03616743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation about the links between smoking and chronic pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief smoking control arm
Description: Psychoeducation about the general adverse effects of smoking.
Study: NCT03338556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP-001

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02117817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabpaclitaxel
Description: Given IV
Study: NCT03338556

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02786862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: independent ventilation
Description: comparison conventional and independent 1:1 ventilation
Study: NCT03232112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 2 MG Injection
Description: Subcutaneous injection once-weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BD PosiFlush (saline)
Description: Subcutaneous injection once-weekly
Study: NCT01912885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 1-1
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 1-2
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 2-1
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 2-2
Description: Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS 0-1
Description: Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
Study: NCT01809236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: intravitreal injection of 0.5 mg Conbercept
Study: NCT03283839

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Posturography
Description: Evaluation of postural control and of orientation function

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Posturography
Description: Evaluation of postural control and of orientation function
Study: NCT03910192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based coaching
Description: 16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary cardiovascular risk reduction coaching
Description: Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
Study: NCT02997124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local infiltration and TAP block
Description: Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local infiltration only
Description: Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
Study: NCT03877744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive virtual presence
Description: parents will install car seat through remote guidance via interactive virtual presence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: live technician
Description: parents will install car seat through guidance from a live certified technician who is present
Study: NCT03868722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
Study: NCT04259710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-setting intervention
Description: The participant will meet weekly with the investigator, report steps and set goals for the following week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Description: The participant will meet weekly with the investigator, report steps and set goals for the following week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting with implementation intentions
Description: In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pedometer only
Description: the participant will be given a pedometer and instructed how to use it.
Study: NCT04289883

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nano-particulated whey protein vs non-particulated whey protein (control)
Description: Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High molecular weight whey protein-alginate coacervates vs calcium alginate (control)
Description: Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
Study: NCT02214173

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rice bran arabinoxylan compound (RBAC)
Description: 2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
Study: NCT03730389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Physical Vibration Lithecbole (EPVL)
Description: Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
Study: NCT02363647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor Genomic Analysis
Description: Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process.
Study: NCT03933501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and metronidazole
Description: 375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin and metronidazole
Description: 375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
Study: NCT01145222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A. CNS 7056
Description: Initial low dose plus supplemental doses as necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B. CNS 7056
Description: Initial intermediate dose plus supplemental doses as necessary.
Study: NCT03933501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
Study: NCT00600002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
Study: NCT04611477

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice Hulk
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic365 Ver 5
Description: Active Comparator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic365 Ver 7
Description: Active Comparator
Study: NCT02169076

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cardiac Resynchronization Therapy
Description: The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy
Description: The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
Study: NCT01789879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.